Sensei Biotherapeutics Gestione
Gestione criteri di controllo 2/4
Sensei Biotherapeutics' CEO is John Celebi, appointed in Feb 2018, has a tenure of 6.75 years. total yearly compensation is $1.01M, comprised of 52.6% salary and 47.4% bonuses, including company stock and options. directly owns 0.25% of the company’s shares, worth $30.63K. The average tenure of the management team and the board of directors is 1.9 years and 3.8 years respectively.
Informazioni chiave
John Celebi
Amministratore delegato
US$1.0m
Compenso totale
Percentuale dello stipendio del CEO | 52.6% |
Mandato del CEO | 6.8yrs |
Proprietà del CEO | 0.2% |
Durata media del management | 1.9yrs |
Durata media del Consiglio di amministrazione | 3.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?
Nov 03We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully
Jul 02Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Mar 14We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely
Aug 14Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06
Aug 09Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Apr 18Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans
Nov 16Analisi delle retribuzioni degli amministratori delegati
Data | Compenso totale | Stipendio | Guadagni aziendali |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$30m |
Mar 31 2024 | n/a | n/a | -US$32m |
Dec 31 2023 | US$1m | US$532k | -US$34m |
Sep 30 2023 | n/a | n/a | -US$39m |
Jun 30 2023 | n/a | n/a | -US$45m |
Mar 31 2023 | n/a | n/a | -US$46m |
Dec 31 2022 | US$2m | US$513k | -US$49m |
Sep 30 2022 | n/a | n/a | -US$46m |
Jun 30 2022 | n/a | n/a | -US$42m |
Mar 31 2022 | n/a | n/a | -US$41m |
Dec 31 2021 | US$7m | US$487k | -US$37m |
Sep 30 2021 | n/a | n/a | -US$33m |
Jun 30 2021 | n/a | n/a | -US$28m |
Mar 31 2021 | n/a | n/a | -US$23m |
Dec 31 2020 | US$2m | US$395k | -US$20m |
Compensazione vs Mercato: John's total compensation ($USD1.01M) is above average for companies of similar size in the US market ($USD655.65K).
Compensazione vs guadagni: John's compensation has been consistent with company performance over the past year.
AMMINISTRATORE DELEGATO
John Celebi (52 yo)
6.8yrs
Mandato
US$1,012,289
Compensazione
Mr. John K. Celebi, MBA serves as President, Chief Executive Officer and Director of Alvaxa Biosciences, Incorporated since February 2018. Mr. Celebi serves as President and Chief Executive Officer of Sens...
Gruppo dirigente
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
President | 6.8yrs | US$1.01m | 0.25% $ 30.6k | |
Chief Scientific Officer | 1.9yrs | US$739.08k | 0.14% $ 17.4k | |
Senior VP of Finance | less than a year | Nessun dato | Nessun dato | |
Vice President of Investor Relations & Communications | no data | Nessun dato | Nessun dato | |
Senior VP | 2.3yrs | Nessun dato | Nessun dato | |
Chief Business Officer | less than a year | Nessun dato | Nessun dato | |
Chief Medical Officer | no data | Nessun dato | Nessun dato |
1.9yrs
Durata media
50yo
Età media
Gestione esperta: SNSE's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Membri del Consiglio di amministrazione
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
President | 6.8yrs | US$1.01m | 0.25% $ 30.6k | |
Independent Director | 8.9yrs | US$75.56k | 1.35% $ 166.3k | |
Independent Chairman | 2.7yrs | US$101.57k | 0.063% $ 7.8k | |
Independent Director | 7.8yrs | US$73.39k | 0.084% $ 10.4k | |
Member of Immuno-Oncology Advisory Board | 3.5yrs | Nessun dato | Nessun dato | |
Independent Director | 3.8yrs | US$69.32k | 0.018% $ 2.2k | |
Independent Director | 4.8yrs | US$68.43k | Nessun dato | |
Member of Immuno-Oncology Advisory Board | no data | Nessun dato | Nessun dato | |
Member of Immuno-Oncology Advisory Board | 3.5yrs | Nessun dato | Nessun dato | |
Independent Director | 3.3yrs | US$62.24k | 0.018% $ 2.2k | |
Member of Immuno-Oncology Advisory Board | no data | Nessun dato | Nessun dato | |
Member of Immuno-Oncology Advisory Board | no data | Nessun dato | Nessun dato |
3.8yrs
Durata media
60yo
Età media
Consiglio di amministrazione esperto: SNSE's board of directors are considered experienced (3.8 years average tenure).